Fresenius Medical Care AG (NYSE:FMS) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. boosted its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,287 shares of the company’s stock after buying an additional 1,398 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Fresenius Medical Care were worth $1,456,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Allworth Financial LP increased its stake in Fresenius Medical Care by 53.1% in the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in Fresenius Medical Care by 4.5% in the second quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company’s stock valued at $278,000 after purchasing an additional 624 shares during the last quarter. MML Investors Services LLC increased its position in shares of Fresenius Medical Care by 5.3% in the third quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after buying an additional 753 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Fresenius Medical Care by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company’s stock worth $345,000 after buying an additional 1,128 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Fresenius Medical Care by 8.5% in the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after buying an additional 1,207 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Performance

Shares of FMS opened at $24.63 on Friday. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $24.67. The company’s 50 day simple moving average is $22.87 and its 200 day simple moving average is $21.00. The company has a market capitalization of $14.45 billion, a price-to-earnings ratio of 20.35, a PEG ratio of 0.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. The business had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same quarter last year, the firm earned $0.31 earnings per share. On average, sell-side analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial raised their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, StockNews.com started coverage on Fresenius Medical Care in a research report on Friday, January 3rd. They issued a “strong-buy” rating on the stock.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.